http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Lineage Establishes New R&D Facility in U.S. and Expands Current GMP Manufacturing Facility in Israel
-
Lineage to Present at H.C. Wainwright & Co. 2nd Annual Virtual Ophthalmology Conference
-
Lineage Cell Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
-
Lineage Cell Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on August 11, 2022
-
Lineage Broadens Collaboration With Advanced BioMatrix for HyStem® Cell Drug Delivery Technology
-
Lineage Cell Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
-
Lineage Cell Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on May 12, 2022
-
Lineage Cell Therapeutics (LCTX) Reports RG6501 Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Relate
-
RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration
-
Lineage to Present at B. Riley Securities 2022 Neuro & Ophthalmology Virtual Investor Conference on April 27, 2022
-
Lineage Announces a Fifth Cell Therapy Program: Allogeneic Photoreceptor Transplants for the Treatment of Diseases Which May Lead to Blindness
-
Lineage and Cancer Research UK Announce Completion of Patient Enrollment in Phase 1 Clinical Study of VAC2 for the Treatment of Non-small Cell Lung Cancer
-
Lineage to Present at the NobleCon18 Investor Conference on April 20, 2022
-
Lineage to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC on March 28, 2022
-
Lineage Announces Pipeline Expansion to Include Auditory Neuronal Cell Therapy for Treatment of Hearing Loss
-
RG6501 (OpRegen®) Full Phase 1/2a Results to Be Featured at 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Allen C. Ho, M.D., FACS
-
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
-
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update on March 10, 2022
-
Lineage to Present at B. Riley Securities 2022 Virtual Oncology Conference on January 27, 2022
-
Lineage Cell Therapeutics to Present at H.C. Wainwright Bioconnect Virtual Conference
-
Lineage Establishes Exclusive Worldwide Collaboration With Genentech for the Development and Commercialization of OpRegen® RPE Cell Therapy for the Treatment of Ocular Disorders
-
Lineage Reports Fourth Case of Retinal Tissue Restoration With OpRegen®
-
OpRegen® Clinical Data Presented at 125th Annual American Academy of Ophthalmology Meeting by Michael S. Ip, M.D.
-
Lineage Reports Third Quarter 2021 Financial Results and Highlights Progress From Clinical Cell Therapy Programs
-
Lineage Cell Therapeutics to Report Third Quarter 2021 Financial Results and Provide Business Update on November 10, 2021
-
OpRegen® Data Update to Be Featured at 2021 American Academy of Ophthalmology Annual Meeting in Presentation by Michael S. Ip, M.D.
-
Lineage to Be Featured in B. Riley Securities Fall 2021 “Growth Biotech Best Ideas” Virtual Series on October 18, 2021
-
Lineage Cell Therapeutics (LCTX) Announces Promising New OpRegen Clinical Data Featured at 54th Annual Retina Society Meeting
-
Promising New OpRegen® Clinical Data Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.
-
Lineage to Present at the 2021 Cantor Virtual Global Healthcare Conference on September 27, 2021
-
Lineage Cell (LCTX) Announces Data From Clinical Trial Continues to Demonstrate Single Administration of OpRegen Can Provide Anatomical and Functional Improvements in Patients With Dry AMD With Geogra
-
Data From Ongoing Clinical Trial Continues to Demonstrate a Single Administration of OpRegen® Can Provide Anatomical and Functional Improvements in Patients With Dry AMD With Geographic Atrophy
-
Opregen® Data Update Will Be Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.
-
Lineage Announces Appointment of General Counsel
-
Lineage Reports Second Quarter 2021 Financial Results and Highlights Additional Progress From Clinical Cell Therapy Programs
-
Lineage to Present at the H.C. Wainwright Ophthalmology Conference on August 17, 2021
-
Lineage Cell Therapeutics to Report Second Quarter 2021 Financial Results and Provide Business Update on August 12, 2021
-
Lineage Cell Therapeutics (LCTX) Says OpRegen Clinical Data Continues to Demonstrate Functional and Anatomical Improvements in Patients With Dry AMD With Geographic Atrophy
-
OpRegen® Clinical Data Continues to Demonstrate Functional and Anatomical Improvements in Patients With Dry AMD With Geographic Atrophy
-
OpRegen® Data Update to Be Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.
-
Lineage Cell Therapeutics Joins Russell 3000® and Russell Microcap® Indexes
-
Lineage’s OPC1 Cell Therapy for the Treatment of Spinal Cord Injury to Return to Clinical Testing
-
Lineage Cell Therapeutics (LCTX) Announces Exclusive Option Agreement With Amasa Therapeutics for Supply and Use of Clinical-Grade Hystem
-
Lineage Announces Exclusive Option Agreement With Amasa Therapeutics for Supply and Use of Clinical-Grade Hystem®
-
Lineage Cell Therapeutics (LCTX) Announces Kevin L. Cook to Join as Chief Financial Officer
-
Lineage Cell Therapeutics Announces Kevin L. Cook to Join as Chief Financial Officer
-
Lineage Cell Therapeutics to Present at Raymond James 2021 Human Health Innovation Conference on June 22, 2021
-
Lineage Cell Therapeutics Set to Join Russell 3000® Index and Russell Microcap® Index
-
Lineage Cell Therapeutics to Host Webinar With Therapeutic Area Experts to Discuss Retinal Tissue Restoration Observed in Dry AMD Patients Treated With OpRegen®
-
Lineage Cell Therapeutics (LCTX) Reports Additional Cases of Retinal Tissue Restoration in Dry AMD Patients Treated With OpRegen RPE Cells

